Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019097 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Multiple Myeloma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019097: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019097 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019097, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus vaccine therapy and chemotherapy in treating patients who have multiple myeloma.
Interventions
- DRUG melphalan
- DRUG sargramostim
- DRUG autologous tumor cell vaccine
- DRUG keyhole limpet hemocyanin
Trial Details
| Field | Value |
|---|---|
| Start Date | 1995-07 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019097
The ClinicalTrials.gov registry entry for NCT00019097 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which melphalan is the first listed.
NCT00019097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019097 about?
NCT00019097 is a clinical study titled "Vaccine Therapy in Treating Patients With Multiple Myeloma". RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the eff...
What is the current status of trial NCT00019097?
This trial is currently completed. It is a Phase 2 study. The study started on 1995-07. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00019097?
The interventions under investigation include: melphalan (DRUG), sargramostim (DRUG), autologous tumor cell vaccine (DRUG), keyhole limpet hemocyanin (DRUG).
Who is sponsoring clinical trial NCT00019097?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.